OBT has a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies aimed at meeting needs in the field of cancer. OBT's IO discovery process provides insight into the cancer - immune cell synapse, and has identified several novel IO candidates for cancer therapy.